Association of Dipeptidyl Peptidase-4 Inhibitor Use and Amyloid Burden in Patients With Diabetes and AD-Related Cognitive Impairment
- 14 September 2021
- journal article
- research article
- Published by Wolters Kluwer Health in Neurology
- Vol. 97 (11) , E1110-E1122
Abstract
Objectives: To investigate whether dipeptidyl peptidase-4 inhibitors (DPP-4i) have beneficial effects on amyloid aggregation and longitudinal cognitive outcome in diabetic Alzheimer’s disease-related cognitive impairment (ADCI). Methods: We retrospectively reviewed 282 patients with ADCI who had positive scan of 18F-florbetaben amyloid PET images were classified into three groups according to a prior diagnosis of diabetes and DPP-4i use: diabetic patients being treated with (ADCI-DPP-4i+, n=70) or without DPP-4i (ADCI-DPP-4i-, n=71), and non-diabetic patients (n=141). Multiple linear regression analyses were performed to determine inter-group differences in global and regional amyloid retention using standardized uptake value ratios calculated from cortical areas. We assessed the longitudinal changes in Mini-Mental State Examination (MMSE) score using a linear mixed model. Results: The ADCI-DPP-4i+ group had lower global amyloid burden than the ADCI-DPP-4i− group (β = 0.075, SE = 0.024, p = 0.002) and the non-diabetic ADCI group (β = 0.054, SE = 0.021, p = 0.010) after adjusting for age, sex, education, cognitive status, and APOE ε4 carrier status. Additionally, the ADCI-DPP-4i+ group had lower regional amyloid burden in temporo-parietal areas than either the ADCI-DPP-4i− group or the non-diabetic ADCI group. The ADCI-DPP-4i+ group showed a slower longitudinal decrease in MMSE score (β = 0.772, SE = 0.272, p = 0.005) and memory recall sub-score (β = 0.291, SE = 0.116, p = 0.012) than the ADCI-DPP-4i− group. Conclusions: These findings suggest that DPP-4i use is associated with low amyloid burden and favorable long-term cognitive outcome in diabetic patients with ADCI.Keywords
This publication has 45 references indexed in Scilit:
- Dipeptidyl peptidase IV, aminopeptidase N and DPIV/APN-like proteases in cerebral ischemiaJournal of Neuroinflammation, 2012
- 101 Labeled Brain Images and a Consistent Human Cortical Labeling ProtocolFrontiers in Neuroscience, 2012
- Amyloid‐beta plaque growth in cognitively normal adults: Longitudinal [11C]Pittsburgh compound B dataAnnals of Neurology, 2011
- Longitudinal assessment of Aβ and cognition in aging and Alzheimer diseaseAnnals of Neurology, 2011
- Biomarkers Predicting Alzheimer's Disease in Cognitively Normal AgingJournal of Clinical Neurology, 2011
- How does diabetes accelerate Alzheimer disease pathology?Nature Reviews Neurology, 2010
- Long-term inhibition of dipeptidyl peptidase-4 in Alzheimer’s prone miceExperimental Gerontology, 2010
- Mutated recombinant human glucagon-like peptide-1 protects SH-SY5Y cells from apoptosis induced by amyloid-β peptide (1–42)Neuroscience Letters, 2008
- An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interestNeuroImage, 2006
- Glucagon‐like peptide‐1 decreases endogenous amyloid‐β peptide (Aβ) levels and protects hippocampal neurons from death induced by Aβ and ironJournal of Neuroscience Research, 2003